Back to top
more

Exelixis (EXEL)

(Delayed Data from NSDQ)

$26.46 USD

26.46
1,365,663

+0.15 (0.57%)

Updated Sep 13, 2024 04:00 PM ET

After-Market: $26.44 -0.02 (-0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Exelixis (EXEL) Down 3.4% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Dyne Reports Mixed Data From DMD Study, Key Executives Step Down

by Zacks Equity Research

DYN's shares plummet following mixed data from its ongoing DMD study. Senior executives of the company step down.

Denali Plans to File for Accelerated Approval of Hunter Syndrome Drug

by Zacks Equity Research

DNLI's recent meeting with the FDA was successful and provides the path to file for accelerated approval of tividenofusp alfa for the treatment of MPS II and its subsequent conversion to full approval.

Terns Surges 29.6% in Three Months: Will the Momentum Continue?

by Zacks Equity Research

TERN has outperformed the industry in the past three months on encouraging pipeline progress of its candidates. Positive data on obesity candidates should boost the stock further.

Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Bayer Presents Encouraging Data From Late-Stage Cardiovascular Study

by Zacks Equity Research

BAYRY's late-stage FINEARTS-HF study on finerenone show statistically significant improvement in cardiovascular outcomes in adults with common form of heart failure.

Bayer Initiates Late-Stage Study on Investigational NSCLC Drug

by Zacks Equity Research

BAYRY enrolls the first patient in the phase III SOHO-02 study among treatment-na??ve patients with advanced NSCLC with HER2-activating mutations.

Zacks.com featured highlights Genpact, MPLX, Exelixis, Paramount Global and H&R Block

by Zacks Equity Research

Genpact, MPLX, Exelixis, Paramount Global and H&R Block have been highlighted in this Screen of The Week article.

EXEL vs. CSLLY: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

EXEL vs. CSLLY: Which Stock Is the Better Value Option?

Novartis' Cholesterol Drug Meets Primary Goals in Late-Stage Study

by Zacks Equity Research

NVS' late-stage study meets its primary endpoints, demonstrating the superiority of Leqvio monotherapy over both placebo and ezetimibe in LDL-C reduction.

Why Exelixis (EXEL) is a Top Value Stock for the Long-Term

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Bayer, NextRNA to Develop Therapeutics Targeting Oncology

by Zacks Equity Research

BAYRY collaborates with NextRNA Therapeutics to develop small molecule therapeutics targeting lncRNAs in oncology.

Urmimala Biswas headshot

5 Top-Ranked Value Stocks With Discounted PEG Ratio to Buy

by Urmimala Biswas

Five PEG-based stocks that fulfill our screening criteria are Genpact, MPLX, Exelixis, Paramount Global and H&R Block.

Roche Obtains Approval For its Rare Blood Disorder Drug in the EU

by Zacks Equity Research

RHHBY gets approval for PiaSky for treating patients suffering from paroxysmal nocturnal hemoglobinuria in the EU.

Why Exelixis (EXEL) Might be Well Poised for a Surge

by Zacks Equity Research

Exelixis (EXEL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Bayer (BAYRY) Starts Mid-Stage Study on Chronic Kidney Disease Drug

by Zacks Equity Research

Bayer (BAYRY) advances its pipeline candidate BAY3283142 into phase II for the treatment of chronic kidney disease.

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

EXEL or CSLLY: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

EXEL vs. CSLLY: Which Stock Is the Better Value Option?

Exelixis (EXEL) Gains 14.9% in a Week on Strong Q2 Results

by Zacks Equity Research

Exelixis' (EXEL) shares rally following an impressive performance in the second quarter, buoyed by a surge in license revenues.

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

ADMA Biologics Inc (ADMA) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

Adma Biologics (ADMA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Investing in Exelixis (EXEL)? Don't Miss Assessing Its International Revenue Trends

by Zacks Equity Research

Review Exelixis' (EXEL) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.

Exelixis (EXEL) Q2 Earnings Beat, Milestone Payments Fuel Revenues

by Zacks Equity Research

Exelixis (EXEL) beats on earnings and sales in the second quarter. Its shares are trading up in response to the results.

Exelixis (EXEL) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for Exelixis (EXEL) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Exelixis (EXEL) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Exelixis (EXEL) delivered earnings and revenue surprises of 127.03% and 36.09%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?